Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-adapted first-line treatment for large B-cell lymphoma
ISRCTN11786724Phase 2Recruiting
- Sponsor
- University of Southampton
- Start
- Sep 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, open-label trial of epcoritamab, rituximab, polatuzumab vedotin, cyclophosphamide, vincristine and 2 more in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by University of Southampton. Primary endpoints: Proportion identified as high-risk and Progression-free survival in high-risk participants. Started Sep 2026; status: recruiting.
02
Drugs
epcoritamabrituximabpolatuzumab vedotincyclophosphamidevincristine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ISRCTN11786724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11786724.